CSL Aktsia

CSL EBIT kasv

Delisted·19. juuni 2026

Aastane EBIT kasv ettevõttest CSL (CSL.AX) seisuga 15. aug 2026 on 7,66 %. Eelmisel aastal oli Aastane EBIT kasv 17,18 % — muutus −55,42% (madalam).

EBIT kasv

7,66 %

YoY

−55,42%

Viimati uuendatud:

Aastane EBIT kasv ettevõttest CSL on 2026 7,66 % . Aastane EBIT kasv ettevõttest CSL oli 2025 17,18 % . See väheneb −55,42% madalam võrreldes eelmise aastaga.
Access this data via the Eulerpool API

CSL Aktsiate analüüs

Mida CSL teeb? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused CSL aktsia kohta

CSL Aastane EBIT kasv on 2026. aastal 7,66 %.

Eulpoolist leiate Aastane EBIT kasv CSL täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

EBIT kasv mõõdab operatiivse kasumi protsentuaalset muutust. See näitab, kas ettevõtte põhitegevus muutub kasumlikkemaks.

Aastane EBIT kasv hindamiseks on oluline võrrelda seda sama tööstuse ja sektori ettevõtetega. Eulpoolis leiate Aastane EBIT kasv jaoks otsesed tööstusesisesed võrdlused.

Aastane EBIT kasv on investorite jaoks määrav tegur. Selle näitaja muutused võivad signaliseerida põhialuste paranemist või halvenemist, mõjutades otseselt aktsia hinda. Eulpoolis saate Aastane EBIT kasv CSL ajaloolist arengut ja reaalajas andmeid jälgida.

Access this data via the Eulerpool API

Kasv — CSL

Kõik finantsnäitajad — CSL